Brief: Botanix Pharmaceuticals Says Planned Approval Date For Sofpironium Bromide Remains On Track For Sept
03/04/2023 02:19
April 3 (Reuters) - Botanix Pharmaceuticals Ltd
BOT.AX :
* PLANNED APPROVAL DATE FOR SOFPIRONIUM BROMIDE REMAINS ON
TRACK
FOR SEPTEMBER 2023
Source text for Eikon: ID:nASX9hSsPp
Further company coverage: BOT.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Botanix Pharmaceuticals
See all newsBrief: Botanix Pharmaceuticals Receives Notice Of Allowance For Additional US Patent Covering Sofdra Drug Substance
Brief: Botanix Pharmaceuticals Appoints Paul Seaback As Chief Operating Officer
Brief: Botanix Pharmaceuticals Reaches Term Sheet Agreement With Second API Supplier
Botanix Pharmaceuticals jumps on supply agreement with PPL Pharma Solutions
Brief: Botanix Pharmaceuticals Posts HY Loss Attributable A$33.2 Million